EU Regulatory Maze Threatens Engineered Living Materials

Engineered living materials combining bacteria, yeast, or fungi with synthetic genetic circuits face severe commercial hurdles due to unclear European approval pathways, Phys.org reported on Friday.

These novel substances use living organisms to perform active functions like repairing structural cracks, capturing carbon dioxide, or treating skin conditions. Yet the legal frameworks governing them remain fraught with ambiguity.

Companies struggle to determine which regulatory bodies hold jurisdiction over products that bridge biotechnology and traditional manufacturing. Developers cannot easily predict the time or capital required to clear European compliance hurdles.

The academic study Law and Economics of Regulation of Engineered Living Materials in the EU, published in SpringerBriefs in Law by Kai P. Purnhagen and Wesseler, highlights specific regulatory contradictions.

Consider a construction brick embedded with genetically modified microorganisms designed to precipitate calcium carbonate and seal fractures. Under current European rules, such items must meet strict “contained use” standards to prevent biological escape.

Wesseler explained to Phys.org that qualifying under EU “contained use” provisions requires proof that microbes stay properly isolated. "But how can you demonstrate this for a material that may become damaged during use? And which regulations apply if the bacteria can escape after all?"

Similar legal vacuums plague projects like Fungateria, which fuses fungal mycelium networks with engineered bacteria to manufacture biodegradable slippers and active insulation panels.

These composite items break down over time during routine disposal cycles. That physical degradation directly triggers complicated questions regarding genetically modified organism dispersion.

"How should existing GMO regulations be applied to such composite materials?" Wesseler asked Phys.org. As an illustration, what standards govern modified bacteria embedded in a degrading substance that might eventually reach the outside world?

The NextSkins initiative demonstrates a different regulatory friction point by developing a living bandage for eczema out of bacterial cellulose and engineered yeast cells. Applied directly to human tissue, the product mimics skin sensing and repair while secreting therapeutic proteins.

Authorities must decide whether to classify the hybrid construct as a standard medicinal drug, an advanced medical device, or a regulated GMO. Liability adds another layer of financial risk if a living material mutates or produces unexpected metabolic byproducts long after initial deployment.

"Who would be liable for the resulting damage?" Wesseler told Phys.org, noting potential harm from unintended biological outputs. Whether liability falls on the biological material’s maker, the entity building it into an edible item, or the final retailer remains unclear.

Purnhagen and Wesseler argue that European legislation must evolve to evaluate the final product’s actual properties and real-world applications rather than fixating solely on the underlying genetic modification technology.

They advocate for streamlined approval pathways alongside formalized collaboration between the European Food Safety Authority and the European Medicines Agency to prevent R&D flight.

"A European body could help companies prepare their applications for regulatory approval," Wesseler told Phys.org. Such clarity would better inform businesses regarding applicable rules and expectations, while simultaneously accelerating commercial releases.

Photo of author

Technology Desk

Technology Desk at Archyde.

Veterinary Without Borders Expands Laos Mission With Clinical Lectures, Diplomatic Talks

Four centuries of shifting gender and identity take center stage in Catania this week